{"entity":{"id":"nct01499303","kind":"trial","name":"Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer","aka":[],"tldr":"A phase 2 trial of Fostamatinib in Diffuse large B-cell lymphoma, run by AstraZeneca, completed.","summary":"Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer is a phase 2 interventional study registered as NCT01499303 by AstraZeneca, with 101 participants recorded, started 2011-12 and reaching its primary completion in 2013-10. Interventions recorded: Fostamatinib. Conditions recorded: Diffuse Large B-Cell Lymphoma.\n\nLinked to the drug Fostamatinib because the registry names it among its interventions and Diffuse large B-cell lymphoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01499303","url":"https://clinicaltrials.gov/study/NCT01499303"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["fostamatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01499303","phase":"2","setting":"Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)","sponsor":"AstraZeneca","enrolled":101,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01499303/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"fostamatinib","kind":"drug","name":"Fostamatinib","route":"/drugs/fostamatinib/"}]}}